Head and Neck Cancer Clinical Trial
Official title:
Neoadjuvant Cetuximab Monotherapy Followed by Surgery in Squamous Cell Carcinoma of Head and Neck: Phase I/II Study
Primary diagnose HNSCC carcinoma patients eligible for curative surgery will be proposed the
addition of 2 or 3 neoadjuvant cetuximab infusions. The main objective is to reduce to a
minimal delay the time elapsing between last infusion and surgery.
Iterative biomarkers will be taken at 6 time points permitting to investigate expression gen
profile and protein mutation.
This is a Phase I/II trial of neoadjuvant cetuximab monotherapy in the preoperative
treatment of patients with operable HNSCC. It is a monocenter study (St-Luc university
Hospital, Université catholique de Louvain, Brussels).
This part of the trial will determine the safe minimum delay between the neoadjuvant
cetuximab infusion and surgery. The aim is to investigate if cetuximab given 24 hours before
surgery is safe.
Patients will receive cetuximab with a loading dose of 400 mg/m2 for the first
administration followed by 250 mg/m2/week at the second and third administrations, if
applicable. The delay between the last administration of cetuximab and surgery will be
progressively reduced (Figure 1).
Five levels are pre-defined before final administration of 3 preoperative doses of cetuximab
with a 24-hour delay between the last dose of cetuximab and surgery.
Level I: 10-12 days delay between the second cetuximab infusion and surgery (total of 2
doses pre-op) Level II: 6-8 days delay between the second cetuximab infusion and surgery
(total of 2 doses pre-op) Level III: 3-4 days delay between the second cetuximab infusion
and surgery (total of 2 doses pre-op) Level IV: 3-4 days delay between the third cetuximab
infusion and surgery (total of 3 doses pre-op) Level V: 24-hour delay between the third
cetuximab dose and surgery (total of 3 doses pre-op) The cohort size is 3 patients per
level, extended to 6 patients if one "limiting toxicity" is observed. Decision rules are the
same than as in any classic 3+3 phase 1design (Figure 2).
"Limiting toxicity" is defined as (i) any life-threatening (grade 4) surgical complication
or (ii) an unexpected surgical grade 3 toxicity. Unexpected toxicity will be determined by
the safety committee after careful review of the patient file.
The safety committee will consist of the surgical team of UCL Saint-Luc, one external
surgeon, one representative from Merck and the study coordinators.
Patients treated at level V will be evaluated like patients in the phase II part.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |